Harold Dvorak : Peregrine Pharmaceuticals KOL : Cancer starts with Inflammation : Part II
...chronic inflammation fuels cancer.
The association between chronic inflammation and tumor development has long been known from the early work of German pathologist Rudolph Virchow. Harvard University pathologist Dr. Harold Dvorak later compared tumors with “wounds that never heal,” noting the similarities between normal inflammation processes that characterize wound healing and tumorigenesis or tumor formation.
Thursday, October 23, 2014 12 noon - 1:00 p.m. Frederic Gaspard Theatre Basic Medical Science Building Bannatyne Campus
YOU AND A GUEST TO THE Thursday, October 23, 2014 12 noon - 1:00 p.m. Frederic Gaspard Theatre Basic Medical Science Building Bannatyne Campus GAIRDNER LECTURE PRESENTED BY HAROLD F. DVORAK MD Mallinckrodt Distinguished Professor of Pathology, Harvard Medical School Director, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center Recipient: Canada Gairdner International Award, 2014 2014
In 1983, Dr. Dvorak and his colleagues were the first to demonstrate that tumor cells secreted vascular endothelial growth factor (VEGF), known at the time as vascular permeability factor or VPF. This seminal discovery provided the molecular basis for the field of angiogenesis. Dr. Dvorak went on to make the critically important observation that tumors behave like “wounds that do not heal” in that the vascular and stromal responses they induce closely mimic those of healing wounds. More recently, his work has characterized the different types of blood vessels that tumors generate and the molecular mechanisms by which they form.
Dr. Dvorak has taught for many years at the Harvard Medical School, and has lectured frequently as a visiting professor and at numerous national and international scientific conferences. He is a fellow of the American Association for the Advancement of Science and of the National Foundation for Cancer Research and has served as President of the American Society for Investigative Pathology which awarded him the 2002 Rous-Whipple award the Gold-headed cane award for his scientific accomplishments. In 2005 he received the Grand Prix Lefoulon-Delalande from the Institut de France and in 2006 the inaugural Albert Szent-Gyorgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research (NFCR).
9:40 am–10:10am (30 mins) VPF/VEGF: Vascular permeability & pathological angiogenesis in tumors, wounds & chronic inflammation Dr.Harold Dvorak 2014 Canada Gairdner International Laureate, Beth Israel Deaconess Medical Center, Boston, MA, USA
1:05 am-1:35pm(30 mins) Targeting immune checkpoints in cancer therapy Dr. James Allison 2014 Canada Gairdner International Laureate, University of Texas, Houston, USA
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!